MiNK Therapeutics, a Phase 1 biotech developing allogenic T cell therapies for cancer and immune-mediated diseases, filed on Tuesday with the SEC to raise up to $50 million.
MiNK Therapeutics' lead program, AGENT-797, is an allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapy targeting cancer and other immune-mediated diseases. The company claims that iNKT cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host disease. AGENT-797 is currently conducting a Phase 1 trial in multiple myeloma patients that is expected to report top-line data in the fourth quarter of 2021.
The New York, NY-based company was founded in 2017 and plans to list on the Nasdaq under the symbol INKT. MiNK Therapeutics filed confidentially on January 22, 2021. Evercore ISI, William Blair, B. Riley Securities, and Baird are the joint bookrunners on the deal. No pricing terms were disclosed.
